{"id":74985,"date":"2026-08-17T13:33:38","date_gmt":"2026-08-17T05:33:38","guid":{"rendered":"https:\/\/flcube.com\/?p=74985"},"modified":"2026-08-17T13:33:39","modified_gmt":"2026-08-17T05:33:39","slug":"cansino-biologics-files-nda-in-china-for-td5cp-a-first-in-nation-adolescent-and-adult-dtap-booster-vaccine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=74985","title":{"rendered":"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CanSino Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6185:HKG\">HKG: 6185<\/a>) announced that it has submitted a <strong>New Drug Application (NDA) in China<\/strong> for its <strong>Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine<\/strong> for individuals aged 6 and above, referred to as <strong>Td5cp for Adolescents and Adults<\/strong>. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>China NMPA<\/td><\/tr><tr><td><strong>Submission Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Td5cp \u2013 Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Individuals aged 6 and older<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Booster vaccination against diphtheria, tetanus, and pertussis in adolescents and adults<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>17 Aug 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>NMPA review; potential first adolescent\/adult DTaP booster approval in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-vaccine-profile-amp-positioning\" class=\"wp-block-heading\">Vaccine Profile &amp; Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product:<\/strong> <strong>Td5cp<\/strong>, a <strong>5\u2011component acellular<\/strong> combined vaccine adsorbed for booster use against <strong>diphtheria, tetanus, and pertussis<\/strong><\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Adolescents and adults aged <strong>6 years and older<\/strong><\/li>\n\n\n\n<li><strong>Role:<\/strong> Booster dose to extend protection beyond childhood immunization, consistent with practice in major developed countries where such vaccines are incorporated into routine immunization schedules<\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> <strong>No adolescent and adult DTaP booster vaccine has been approved in China to date<\/strong>, leaving a first\u2011mover opportunity for Td5cp<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Opportunity:<\/strong> With no approved adolescent\/adult DTaP booster in China, <strong>Td5cp<\/strong> addresses an entirely unserved segment, creating potential to establish a new category in the domestic vaccine market.<\/li>\n\n\n\n<li><strong>Alignment with Global Practice:<\/strong> Major developed countries already include adolescent\/adult pertussis boosters in routine immunization schedules; China&#8217;s lack of an approved product represents a clear gap that public health authorities may seek to close.<\/li>\n\n\n\n<li><strong>Pertussis Resurgence:<\/strong> Waning immunity and pertussis outbreaks in older age groups globally have reinforced the case for adolescent and adult boosting, supporting long\u2011term demand for the vaccine category.<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> The NDA advances <strong>CanSino Biologics&#8217;<\/strong> expansion into routine immunization and preventive care franchises with durable, recurring demand.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, approval outcomes, and commercial expectations for Td5cp. Actual results may differ due to risks including NMPA review decisions, immunization policy adoption, and competitive dynamics in the vaccine market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688185_20260817_M5GA.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688185_20260817_M5GA.\"><\/object><a id=\"wp-block-file--media-41b97674-119f-4421-9ad0-c0e9e4997993\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688185_20260817_M5GA.pdf\">688185_20260817_M5GA<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688185_20260817_M5GA.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-41b97674-119f-4421-9ad0-c0e9e4997993\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[466,884,38,12],"class_list":["post-74985","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cansino-biologics","tag-hkg-6185","tag-market-approval-filings","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in China for its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine for individuals aged 6 and above, referred to as Td5cp for Adolescents and Adults. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=74985\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine\" \/>\n<meta property=\"og:description\" content=\"CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in China for its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine for individuals aged 6 and above, referred to as Td5cp for Adolescents and Adults. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=74985\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T05:33:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T05:33:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74985#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74985\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine\",\"datePublished\":\"2026-08-17T05:33:38+00:00\",\"dateModified\":\"2026-08-17T05:33:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74985\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CanSino Biologics\",\"HKG: 6185\",\"Market approval filings\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74985#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74985\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=74985\",\"name\":\"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-17T05:33:38+00:00\",\"dateModified\":\"2026-08-17T05:33:39+00:00\",\"description\":\"CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in China for its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine for individuals aged 6 and above, referred to as Td5cp for Adolescents and Adults. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74985#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74985\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74985#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine - Insight, China&#039;s Pharmaceutical Industry","description":"CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in China for its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine for individuals aged 6 and above, referred to as Td5cp for Adolescents and Adults. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=74985","og_locale":"en_US","og_type":"article","og_title":"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine","og_description":"CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in China for its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine for individuals aged 6 and above, referred to as Td5cp for Adolescents and Adults. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.","og_url":"https:\/\/flcube.com\/?p=74985","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-17T05:33:38+00:00","article_modified_time":"2026-08-17T05:33:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=74985#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=74985"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine","datePublished":"2026-08-17T05:33:38+00:00","dateModified":"2026-08-17T05:33:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=74985"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CanSino Biologics","HKG: 6185","Market approval filings","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=74985#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=74985","url":"https:\/\/flcube.com\/?p=74985","name":"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-17T05:33:38+00:00","dateModified":"2026-08-17T05:33:39+00:00","description":"CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in China for its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5\u2011Component) Combined Vaccine for individuals aged 6 and above, referred to as Td5cp for Adolescents and Adults. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=74985#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=74985"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=74985#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=74985"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74985\/revisions"}],"predecessor-version":[{"id":74987,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74985\/revisions\/74987"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=74985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=74985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=74985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}